Shanghai Yizhong Pharmaceutical Co Ltd Total Liabilities
Shanghai Yizhong Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Shanghai Yizhong Pharmaceutical Co Ltd (688091) has total liabilities worth CN¥82.76 Million CNY (≈ $12.11 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Shanghai Yizhong Pharmaceutical Co Ltd (688091) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)
Total liabilities of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024. This chart illustrates how Shanghai Yizhong Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Shanghai Yizhong Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Yizhong Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bristow Group Inc
NYSE:VTOL
|
USA | $1.35 Billion |
|
Hisense Home Appliances Group Co. Ltd
F:GKE
|
Germany | €52.36 Billion |
|
Hunan Keli Motor Co Ltd
SHE:002892
|
China | CN¥1.50 Billion |
|
Aurisco Pharmaceutical Co Ltd
SHG:605116
|
China | CN¥1.47 Billion |
|
Alma Media Oyj
HE:ALMA
|
Finland | €271.90 Million |
|
Bank Islam Malaysia Bhd
KLSE:5258
|
Malaysia | RM94.68 Billion |
|
Hunan Oil Pump
SHG:603319
|
China | CN¥1.72 Billion |
|
S.ENER.ELEC.SP.GDR REGS 1
F:ECEA
|
Germany | €8.78 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Shanghai Yizhong Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Shanghai Yizhong Pharmaceutical Co Ltd balance sheet assets.
Liquidity & Leverage Metrics
Shanghai Yizhong Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Shanghai Yizhong Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Yizhong Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual total liabilities of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥42.97 Million ≈ $6.29 Million |
-60.40% |
| 2023-12-31 | CN¥108.52 Million ≈ $15.88 Million |
+206.43% |
| 2022-12-31 | CN¥35.42 Million ≈ $5.18 Million |
+41.54% |
| 2021-12-31 | CN¥25.02 Million ≈ $3.66 Million |
+63.50% |
| 2020-12-31 | CN¥15.30 Million ≈ $2.24 Million |
+24.79% |
| 2019-12-31 | CN¥12.26 Million ≈ $1.79 Million |
-28.49% |
| 2018-12-31 | CN¥17.15 Million ≈ $2.51 Million |
+6.02% |
| 2017-12-31 | CN¥16.17 Million ≈ $2.37 Million |
-- |
About Shanghai Yizhong Pharmaceutical Co Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was… Read more